Recent Updates
Recently added Catalysts
AEMD Positive Sentiment Score: 75/100

Aethlon Medical to Participate in the 2024 Maxim Healthcare Virtual Summit

Tuesday, October 8, 2024 2 min read
Key Takeaway: Aethlon Medical, Inc. (AEMD) will participate in the 2024 Maxim Healthcare Virtual Summit on October 15, 2024. CEO and CFO James Frakes will engage in a fireside chat during the event, which is hosted by Anthony Vendetti. The company focuses on innovative treatment solutions, particularly the Hemopurifier, designed to combat cancer and severe viral infections. The Hemopurifier has received FDA Breakthrough Device designation, highlighting its potential in addressing serious health conditions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aethlon Medical is participating in a significant industry event.
  • The Hemopurifier is recognized as an FDA-designated Breakthrough Device.
  • The technology presents potential applications in treating severe conditions.

Full Press Release Details

SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that James Frakes, Chief Executive Officer and Chief Financial Officer, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, hosted by Anthony Vendetti, executive managing director and head of research at Maxim Group, on Tuesday, October 15, 2024 at 4:30 pm ET.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Additional information can be found at www.AethlonMedical.com.
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
S.A. Noonan Communications, LLC
SOURCE Aethlon Medical, Inc.

21 %

more press release views with

Frequently Asked Questions

What company is developing the Hemopurifier?

Aethlon Medical, Inc. is developing the Hemopurifier.

What is the main use of the Hemopurifier?

The Hemopurifier is designed to combat cancer and life-threatening viral infections.

What designation has the Hemopurifier received from the FDA?

It holds the FDA's Breakthrough Device designation for specific cancer treatments.

When will James Frakes speak at the Maxim Healthcare Summit?

James Frakes will participate on October 15, 2024, at 4:30 pm ET.

What technology does the Hemopurifier utilize?

The device uses proprietary lectin-based technology to remove harmful exosomes.

Tags: AEMD Viatris Investor Conferences Healthcare Aethlon Medical Maxim Healthcare Hemopurifier FDA Breakthrough Device
Last updated: Oct 8, 2024